Literature DB >> 7811445

Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and presence of white coat hypertension. Results of the HALT Study. Hypertension and Lipid Trial Study Group.

T G Pickering1, M Levenstein, P Walmsley.   

Abstract

In this study the effects of a single daily dose of doxazosin (an alpha-adrenergic blocker) given at night were evaluated in 112 patients with mild hypertension. Patients were studied first on no medication, and a second time after being treated for up to 16 weeks with doxazosin. Blood pressure (BP) was measured by noninvasive ambulatory monitoring at the beginning and end of the study. Before treatment, the white coat effect (clinic-ambulatory BP) was greater in women than in men (significant for systolic pressure but not diastolic), and greater in elderly (aged over 65 years) than in younger patients (significant for both systolic and diastolic pressure). Clinic and ambulatory BP were reduced to a similar extent in men and women by doxazosin, but in the elderly the fall in clinic BP was associated with a much smaller fall of ambulatory BP. In patients with white coat hypertension (elevated clinic but normal ambulatory BP) doxazosin lowered clinic but not ambulatory BP, while in those with sustained hypertension it lowered both.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7811445     DOI: 10.1093/ajh/7.9.848

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  9 in total

1.  Response.

Authors:  Mark Gelfer; Martin Dawes; Janusz Kaczorowski; Raj Padwal; Lyne Cloutier
Journal:  Can Fam Physician       Date:  2016-04       Impact factor: 3.275

2.  Morning blood pressure surge is associated with arterial stiffness and sympathetic baroreflex sensitivity in hypertensive seniors.

Authors:  Yoshiyuki Okada; M Melyn Galbreath; Shigeki Shibata; Sara S Jarvis; Tiffany B Bivens; Wanpen Vongpatanasin; Benjamin D Levine; Qi Fu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-07-05       Impact factor: 4.733

Review 3.  Treatment of white coat hypertension.

Authors:  S G Chrysant
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

4.  Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy.

Authors:  N Martell; M Luque
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Jul-Aug       Impact factor: 3.738

Review 5.  Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population.

Authors:  Stanley S Franklin; Lutgarde Thijs; Tine W Hansen; Yan Li; José Boggia; Masahiro Kikuya; Kristina Björklund-Bodegård; Takayoshi Ohkubo; Jørgen Jeppesen; Christian Torp-Pedersen; Eamon Dolan; Tatiana Kuznetsova; Katarzyna Stolarz-Skrzypek; Valérie Tikhonoff; Sofia Malyutina; Edoardo Casiglia; Yuri Nikitin; Lars Lind; Edgardo Sandoya; Kalina Kawecka-Jaszcz; Yutaka Imai; Jiguang Wang; Hans Ibsen; Eoin O'Brien; Jan A Staessen
Journal:  Hypertension       Date:  2012-01-17       Impact factor: 10.190

Review 6.  Ambulatory blood pressure monitoring in the diagnosis and management of hypertension.

Authors:  Ehud Grossman
Journal:  Diabetes Care       Date:  2013-08       Impact factor: 19.112

Review 7.  White-coat hypertension should not be treated in subjects with diabetes.

Authors:  Michael Bursztyn; Iddo Z Ben-Dov
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

8.  Should white coat hypertension be treated?

Authors:  Thomas G Pickering
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-09       Impact factor: 3.738

9.  Design and study protocol for a cluster randomized trial of a multi-faceted implementation strategy to increase the uptake of the USPSTF hypertension screening recommendations: the EMBRACE study.

Authors:  Nathalie Moise; Erica Phillips; Eileen Carter; Carmela Alcantara; Jacob Julian; Anusorn Thanataveerat; Joseph E Schwartz; Siqin Ye; Andrea Duran; Daichi Shimbo; Ian M Kronish
Journal:  Implement Sci       Date:  2020-08-08       Impact factor: 7.327

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.